Analysts Set Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) PT at $33.60

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has been assigned a consensus recommendation of “Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $33.60.

Several brokerages recently issued reports on KNSA. Wedbush lifted their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group assumed coverage on Kiniksa Pharmaceuticals in a report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company.

Kiniksa Pharmaceuticals Trading Up 0.3 %

KNSA stock opened at $26.63 on Tuesday. The firm has a 50 day moving average of $25.42 and a 200-day moving average of $21.78. The company has a market cap of $1.89 billion, a price-to-earnings ratio of 242.09 and a beta of 0.33. Kiniksa Pharmaceuticals has a 12-month low of $14.12 and a 12-month high of $27.92.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The business had revenue of $108.30 million for the quarter, compared to analyst estimates of $90.60 million. During the same period in the previous year, the firm earned ($0.02) EPS. The business’s revenue for the quarter was up 51.5% compared to the same quarter last year. Sell-side analysts forecast that Kiniksa Pharmaceuticals will post -0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other news, CFO Mark Ragosa sold 24,248 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $24.79, for a total transaction of $601,107.92. Following the sale, the chief financial officer now owns 19,253 shares in the company, valued at $477,281.87. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CFO Mark Ragosa sold 24,248 shares of the stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $24.79, for a total transaction of $601,107.92. Following the transaction, the chief financial officer now directly owns 19,253 shares in the company, valued at approximately $477,281.87. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Sanj K. Patel sold 136,124 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the completion of the sale, the chief executive officer now owns 63,012 shares of the company’s stock, valued at $1,616,257.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 278,064 shares of company stock worth $7,165,254. Insiders own 54.57% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after buying an additional 1,998 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals during the first quarter worth about $71,000. Ashton Thomas Private Wealth LLC purchased a new position in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth about $100,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Kiniksa Pharmaceuticals by 88.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,708 shares of the company’s stock valued at $152,000 after purchasing an additional 3,611 shares in the last quarter. Finally, Lynx1 Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals during the 2nd quarter worth about $177,000. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.